Ad
related to: zirgan vs viroptic pain medication side effects
Search results
Results From The WOW.Com Content Network
Idoxuridine is an anti-herpesvirus antiviral drug.. It is a nucleoside analogue, a modified form of deoxyuridine, similar enough to be incorporated into viral DNA replication, but the iodine atom added to the uracil component blocks base pairing.
Amprenavir pro-drug: 2003 (FDA), 2004 Foscarnet: Herpes: Pyrophosphate analogue DNA polymerase inhibitor: 1991 Ganciclovir (Cytovene) [9] Cytomegalovirus (CMV) [10] Competitive nucleoside analogue dGTP inhibitor 1988 Ibacitabine: Herpes labialis: Ibalizumab (Trogarzo) [11] HIV Entry inhibitor 2018 Idoxuridine: Herpes: dU analogue inhibitor 1962 ...
Common side effects include headache, feeling tired, nausea, diarrhea, and fever. [3] Severe side effects may include bone marrow suppression, muscle damage, worsening of hepatitis B if previously infected, high blood lactate and liver enlargement. [2] [4] It may be part of a recommended treatment during pregnancy. [2]
Headaches are a common side effect of ED medications such as sildenafil (the active ingredient in Viagra), tadalafil (Cialis) and vardenafil (Levitra), with about 25 percent of men prescribed ...
Side effects from the drugs can include gastrointestinal problems, including abdominal pain, nausea and vomiting. Zepbound contains the active ingredient tirzepatide, the same drug used in Lilly ...
Foscarnet (phosphonomethanoic acid), known by its brand name Foscavir, is an antiviral medication which is primarily used to treat viral infections involving the Herpesviridae family. It is classified as a pyrophosphate analog DNA polymerase inhibitor .
These medications are associated with common side effects like nausea and vomiting, which can intensify when a person consumes certain foods, including high fat, high-sugar items that are often ...
These side effects are serious and some of them are permanent, and many remain a crucial concern for companies and healthcare professionals and substantial efforts are being encouraged to reduce the potential risks for future antipsychotics through more clinical trials and drug development.